Testosterone Cypionate vs Enclomiphene Citrate: Head-to-Head Efficacy Compared

Two Different Mechanisms for the Same Problem

Testosterone cypionate and enclomiphene citrate both treat male hypogonadism, but they operate through opposing endocrine strategies. Cypionate replaces testosterone directly. Enclomiphene stimulates the hypothalamic-pituitary-gonadal (HPG) axis to produce more of it endogenously.

Testosterone cypionate is an esterified form of exogenous testosterone. Once injected, it slowly hydrolyzes in muscle or subcutaneous tissue, releasing bioidentical testosterone over 7 to 14 days 1. The 2018 Endocrine Society Clinical Practice Guideline recommends injectable testosterone esters as first-line pharmacotherapy for symptomatic male hypogonadism with confirmed low morning serum T on two separate measurements 2.

Enclomiphene citrate is the trans-isomer of clomiphene. It blocks estrogen receptors in the hypothalamus, reducing negative feedback and prompting increased GnRH pulsatility. That signals the pituitary to release more LH and FSH, which drive testicular testosterone production and spermatogenesis simultaneously 3. This distinction matters clinically. Exogenous testosterone shuts down the HPG axis through negative feedback, suppressing LH and FSH to near-zero levels within weeks. That suppression leads to reduced intratesticular testosterone, impaired Sertoli cell function, and azoospermia in up to 40% of men on TRT within 6 to 12 months 4.

Testosterone Cypionate: Efficacy Data

Testosterone cypionate is the most prescribed injectable form of TRT in the United States, and decades of trial data support its efficacy for symptom relief and metabolic improvement. No other hypogonadism treatment has a deeper evidence base.

The landmark T-Trials, published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms of hypogonadism 1. Men received transdermal testosterone gel (titrated to mid-normal range) or placebo for 12 months. The Sexual Function Trial showed a significant increase in sexual activity (P<0.001), sexual desire (P=0.009), and erectile function compared with placebo. The Vitality Trial demonstrated a modest but significant improvement in the FACIT-Fatigue score. The Physical Function Trial showed increased 6-minute walking distance, though the magnitude (an average gain of 6.0 meters vs. placebo) did not meet the pre-specified minimum clinically important difference of 50 meters.

Dr. Peter Snyder, lead investigator of the T-Trials, stated: "Testosterone treatment increased serum testosterone levels to the mid-normal range and improved all aspects of sexual function as well as mood and depressive symptoms" 1.

While the T-Trials used transdermal gel, injectable testosterone cypionate achieves comparable or higher steady-state serum levels. A pharmacokinetic study of 200 mg intramuscular testosterone cypionate showed peak levels of approximately 1,000 to 1 to 200 ng/dL at 24 to 48 hours post-injection, with trough levels of 400 to 600 ng/dL at day 14 5. That wider peak-to-trough swing can produce more noticeable energy and libido fluctuations compared to daily topical formulations, though many men prefer the convenience of biweekly injections over daily gel application.

Body composition changes on cypionate are well-documented. A meta-analysis of 59 randomized controlled trials (N=5,331) found that testosterone therapy increased lean body mass by 1.6 kg (95% CI, 1.3 to 2.0) and reduced fat mass by 2.0 kg (95% CI, 1.4 to 2.6) over an average treatment duration of 8.7 months 6.

Enclomiphene Citrate: Efficacy Data

Enclomiphene reliably raises serum testosterone through endogenous pathways and does so without compromising spermatogenesis. That combination is unique among pharmacologic options for male hypogonadism.

Kim et al. published a key 2016 study in BJU International evaluating enclomiphene citrate in men with secondary hypogonadism 3. The trial demonstrated that enclomiphene 25 mg daily raised mean serum testosterone from a baseline of approximately 220 ng/dL to above 400 ng/dL within 12 weeks, while sperm concentration remained stable or improved. LH levels increased from baseline, confirming the drug's mechanism of HPG axis stimulation rather than suppression.

A phase III trial (ZA-304) compared enclomiphene 12.5 mg and 25 mg daily against topical testosterone gel 1.62% and placebo in 261 men with secondary hypogonadism 7. At 16 weeks, both enclomiphene doses normalized morning testosterone (above 300 ng/dL) in over 80% of subjects. The 25 mg group achieved mean total testosterone of approximately 450 ng/dL. Sperm concentration remained within normal limits in both enclomiphene arms, while the testosterone gel group experienced significant declines in sperm concentration and LH suppression.

The absolute testosterone levels achieved with enclomiphene are typically lower than those seen with exogenous cypionate. Most men on enclomiphene 25 mg daily reach a total testosterone between 350 and 550 ng/dL, while men on 100 to 200 mg weekly testosterone cypionate commonly reach 600 to 1 to 000 ng/dL. This gap is relevant for symptom relief: men with more severe hypogonadal symptoms (profound fatigue, loss of morning erections, significant muscle wasting) may find enclomiphene's testosterone elevation insufficient for complete resolution.

Symptom Relief: Direct Comparison of Outcomes

No randomized controlled trial has directly compared testosterone cypionate with enclomiphene citrate using symptom-based endpoints. The comparison below draws from parallel evidence in separate study populations.

Sexual function improves with both therapies, but the magnitude differs. The T-Trials showed a 2.9-point improvement on the Psychosexual Daily Questionnaire desire domain with testosterone gel versus placebo (P<0.001) 1. Data on enclomiphene's impact on validated sexual function instruments are limited. The ZA-304 trial reported "symptomatic improvement" but did not use the same validated scales as the T-Trials, making direct numerical comparison unreliable 7.

Energy and vitality show a similar pattern. Testosterone therapy produced a statistically significant improvement on the FACIT-Fatigue scale in the T-Trials. Anecdotal clinical experience with enclomiphene suggests improvements in energy, but no large trial has measured this with validated fatigue instruments.

Body composition changes are more clearly separated. The 1.6 kg lean mass gain and 2.0 kg fat loss documented across testosterone RCTs 6 have no equivalent data set for enclomiphene. Given that enclomiphene produces lower absolute testosterone levels, the expected anabolic effect is smaller.

Bone mineral density is another area where testosterone has stronger evidence. The Bone Trial within the T-Trials showed significant increases in volumetric bone mineral density and estimated bone strength at the spine and hip after 12 months of testosterone treatment 8. No published trial has evaluated enclomiphene's effects on bone density.

Fertility: Where Enclomiphene Has a Clear Advantage

For men who want to maintain or restore fertility, enclomiphene is the preferred pharmacologic option. This is not debatable based on current evidence. Exogenous testosterone suppresses the HPG axis and impairs spermatogenesis.

A retrospective study of 6,569 men receiving testosterone therapy found that 29% developed oligospermia and 12.4% developed azoospermia within 12 months 4. Recovery of spermatogenesis after discontinuing testosterone therapy takes a median of 6 months, with some men requiring 12 to 24 months, and a small percentage may not fully recover 9.

The 2019 American Urological Association guideline on male infertility explicitly recommends against testosterone therapy in men desiring fertility, stating: "Exogenous testosterone or anabolic steroid use is associated with impaired spermatogenesis and should be discontinued in men trying to conceive" 10.

Enclomiphene avoids this problem entirely. By stimulating LH and FSH, it supports both testosterone production and sperm maturation. In the Kim et al. trial, men on enclomiphene maintained sperm concentrations above 15 million/mL (the WHO lower reference limit) throughout the study period 3. Some men actually saw sperm counts increase during treatment.

Safety and Side-Effect Profiles

Testosterone cypionate carries well-characterized risks that require ongoing laboratory monitoring. Enclomiphene's safety profile is less thoroughly studied but appears favorable in existing data.

Polycythemia (hematocrit above 54%) occurs in 3 to 18% of men on testosterone therapy, depending on dose, route, and baseline hematocrit 2. The Endocrine Society guideline recommends checking hematocrit at 3 to 6 months after starting testosterone, then annually. Men with hematocrit above 54% should have their dose reduced or therapy held until levels normalize.

Other testosterone cypionate risks include acne (reported in up to 20% of users), sleep apnea exacerbation, gynecomastia from aromatization to estradiol, and testicular atrophy from HPG suppression 2. The TRAVERSE trial (N=5,246), published in 2023, provided reassurance on cardiovascular safety: testosterone replacement did not increase the incidence of major adverse cardiovascular events compared with placebo in men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease 11.

Enclomiphene's side-effect profile in clinical trials has been mild. Reported adverse events include headache (5 to 8%), hot flashes (3 to 5%), and mild visual disturbances (<2%) 7. Because it raises estradiol alongside testosterone (both increase proportionally when the HPG axis is stimulated), some men experience nipple tenderness. Enclomiphene does not cause polycythemia, testicular atrophy, or HPG axis suppression.

Choosing Between the Two: A Clinical Decision Framework

The choice between testosterone cypionate and enclomiphene citrate should be driven by three clinical variables: fertility goals, symptom severity, and the underlying cause of hypogonadism.

Primary hypogonadism (testicular failure, Klinefelter syndrome, bilateral orchiectomy) requires exogenous testosterone. Enclomiphene cannot work if the testes cannot respond to LH/FSH stimulation. Serum LH will already be elevated in these men, and adding a SERM produces no meaningful testosterone increase.

Secondary hypogonadism (hypothalamic or pituitary dysfunction, obesity-related HPG suppression, opioid-induced hypogonadism) is where enclomiphene may be most appropriate. The testes are functional but understimulated. Enclomiphene restores the missing signal.

Men planning to conceive within the next 6 to 24 months should avoid testosterone cypionate entirely. Enclomiphene (or clomiphene citrate as an alternative) preserves fertility while treating hypogonadal symptoms. If a man is already on testosterone cypionate and wishes to conceive, transitioning to enclomiphene or hCG should be managed by a reproductive urologist or endocrinologist, with semen analysis monitoring.

Men with no fertility concerns and moderate-to-severe symptoms will typically achieve faster and more complete symptom relief with testosterone cypionate. The higher absolute testosterone levels, proven body composition benefits, and decades of long-term safety data (now including the TRAVERSE cardiovascular safety trial) make cypionate the stronger option for quality-of-life optimization in this population.

Regulatory Status and Access

Testosterone cypionate has been FDA-approved for male hypogonadism since 1979. It is available as a generic from multiple manufacturers. Common brand names include Depo-Testosterone. Insurance coverage is generally available with a confirmed diagnosis of hypogonadism (ICD-10 E29.1) and two morning serum testosterone levels below the lab's reference range 2.

Enclomiphene citrate is not FDA-approved as of May 2026. Androxal (enclomiphene citrate) completed phase III trials but was not granted FDA approval after the agency requested additional studies. The drug is currently available through compounding pharmacies in the United States. Because it lacks FDA approval, insurance coverage is typically unavailable, and patients pay out of pocket. Prescribers should be aware that compounded enclomiphene quality can vary between pharmacies, and sourcing from an accredited 503B outsourcing facility is recommended.

Clomiphene citrate (Clomid), which contains both the enclomiphene (trans) and zuclomiphene (cis) isomers, is FDA-approved for female ovulatory dysfunction and is used off-label for male hypogonadism. Some clinicians prescribe clomiphene as a more accessible alternative to enclomiphene, though the zuclomiphene isomer has a longer half-life and may contribute to estrogenic side effects that enclomiphene alone avoids 12.

Monitoring Protocols Differ

Men on testosterone cypionate require regular lab monitoring: total testosterone (trough level drawn the morning before the next injection), hematocrit, PSA, and estradiol at baseline, 3 months, 6 months, and annually thereafter 2. LH and FSH are suppressed to near zero on exogenous testosterone and do not need serial measurement.

Men on enclomiphene require total testosterone, LH, FSH, and estradiol monitoring. The testosterone-to-estradiol ratio matters: if estradiol rises disproportionately, symptom relief may be blunted despite adequate total testosterone. Hematocrit monitoring is less critical but reasonable at baseline and 6 months. Semen analysis every 6 to 12 months is appropriate for men using enclomiphene specifically for fertility preservation.

Both therapies warrant periodic lipid panels, as testosterone can reduce HDL cholesterol. The TRAVERSE trial reported a small but significant decrease in HDL of approximately 2 mg/dL in the testosterone group compared with placebo 11.